This study is for people with a type of pancreatic cancer called **pancreatic ductal adenocarcinoma (PDAC)**. The study tests two chemotherapy treatments: oxaliplatin and gemcitabine. These are medicines that help slow down or stop cancer growth. The study aims to see if using a special method called the **Transcriptomic Treatment Specific Stratification Signature (TSS)** to decide which treatment is better than using regular methods.

Researchers also want to understand how well people live without cancer coming back and how long they live overall. They will collect samples to learn more about how the body responds to the treatments. This could help create better treatments in the future.

• **Duration**: The study lasts several months with regular hospital visits.
• **Requirements**: Participants must be between 18-79 years old, have had surgery for PDAC, and be able to handle chemotherapy.
• **Risks**: As in any study, there may be side effects. Talk to your doctor to understand them.